Clinical Trials Logo

Clinical Trial Summary

During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole groups. There were 24 subjects who finished the study, 13 from PTU group and 11 from methimazole group. Blood serum was collected for HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin examination. Meanwhile stiffness and thickness of carotid artery was measured using PWV and cIMT.


Clinical Trial Description

This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect. Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia with approval number KET-784/UN.2.F1/ETIK/PPM.00.02/2019. Study participant was observed every month for 3 months. Anti-thyroid drugs (PTU or methimazole) were given according to true simple randomization with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist. At baseline visit, first and third month follow up, blood serum was collected to analyse HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin, meanwhile PWV and cIMT were measured using radiofrequency ultrasound examination of carotid arteries. Categorical data was presented in frequency (%), while numerical data was presented using mean (SD) if normally distributed or median (IQR) if not normally distributed. Correlation Pearson test was performed for normal distributed data and Spearman test for not normal distributed data. To analyze the changes in parameter from baseline, first and third month, repeated ANOVA and General Linear Model test was performed. For not normally distributed data, transformation into normally distributed data was performed and the data was presented as geometric mean (CI 95%). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05118542
Study type Interventional
Source Indonesia University
Contact
Status Completed
Phase Phase 3
Start date January 1, 2019
Completion date August 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Completed NCT02973802 - ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy Phase 1
Completed NCT02491567 - DNA Methylation and Autoimmune Thyroid Diseases
Terminated NCT01320813 - Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy N/A
Completed NCT00432146 - Effect of Lugol's Solution in the Patients With Graves' Disease N/A
Recruiting NCT06081439 - Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
Not yet recruiting NCT06327828 - Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Active, not recruiting NCT04135573 - The Relationship Between NK Cell and Graves' Disease
Recruiting NCT06134219 - Course for Brain Fatigue After Graves' Disease Controlled Study N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Completed NCT03009357 - Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
Recruiting NCT05510609 - Three-dimensional Ultrasonography Thyroid Volume Measurement. N/A
Not yet recruiting NCT06426758 - Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Recruiting NCT05907668 - A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease Phase 2
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting NCT03303053 - Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Phase 3
Recruiting NCT05461820 - Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease Phase 4